Compare TOL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOL | NBIX |
|---|---|---|
| Founded | 1967 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 13.9B |
| IPO Year | 1994 | 1996 |
| Metric | TOL | NBIX |
|---|---|---|
| Price | $147.48 | $128.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 22 |
| Target Price | $163.44 | ★ $175.23 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 2.19 | ★ 4.67 |
| Revenue | ★ $7,143,258,000.00 | $161,626,000.00 |
| Revenue This Year | N/A | $22.85 |
| Revenue Next Year | $6.26 | $9.99 |
| P/E Ratio | $68.32 | ★ $27.78 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $86.67 | $84.23 |
| 52 Week High | $168.36 | $160.18 |
| Indicator | TOL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 40.60 |
| Support Level | $133.98 | $122.82 |
| Resistance Level | $150.45 | $128.99 |
| Average True Range (ATR) | 4.85 | 3.25 |
| MACD | -1.92 | 0.20 |
| Stochastic Oscillator | 11.57 | 27.35 |
Toll Brothers Inc is the luxury homebuilder in the USA, operating in over 60 markets across 24 states. The Fort Washington, Pennsylvania-headquartered homebuilder caters to affluent first-time, move-up, active-adult, and second-homebuyers. Toll Brothers has shifted in recent years to a greater mix of speculative, or "quick move-in" homes. The homebuilder has also expanded its price points, with a greater emphasis on "affordable luxury. Traditional homebuilding accounts for the majority of Toll Brothers' earnings, but the firm also offers ancillary mortgage, title, insurance, and other services.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.